Drugs / Functionally optimized CD33 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07538713 | Jun 2026 → May 2028 expected | acute myeloid leukemia | Qi deng | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Functionally optimized CD33 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07538713 ↗ |
| Known as | FO33 CAR-T | “clinical trial of functionally optimized CD33 CAR-T (FO33 CAR-T) cells for R/R AML” NCT07538713 ↗ |
| Action | Deplete | “FO33 CAR-T cells showed superior cytotoxicity against AML cell lines” NCT07538713 ↗ |
| Modality | Cell therapy | “FO33 CAR-T cells” NCT07538713 ↗ |
| Route | Intravenous | “Functionally optimized CD33 CAR-T intravenous infusion” NCT07538713 ↗ |
| Target | CD33 | “We constructed a lentiviral CAR vector containing the CD33-targeting scFv, 4-1BB, and CD3ζ” NCT07538713 ↗ |